Rheumatologic manifestations of chronic hepatitis C infection

Joint Bone Spine

Volumn 73, Issue 6, 2006, Pages 633-638

  Lormeau, Christian ^a   Falgarone, Géraldine ^a   Roulot, Dominique ^a   Boissier, Marie Christophe ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Arthralgia; Arthritis; Hepatitis C virus; Myalgia; Sicca syndrome; Vasculitis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; FIBROMYALGIA; HEPATITIS C; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; OSTEOSCLEROSIS; POLYARTERITIS NODOSA; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SJOEGREN SYNDROME; STANDARDIZATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; PREVALENCE; REVIEW; VIROLOGY;

AUTOIMMUNE DISEASES; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; RHEUMATIC DISEASES;

EID: 33845506411     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.05.005     Document Type: Short Survey

References (59)

1. WHO. Global surveillance and control of hepatitis C. J. Viral Hepat. 6 (1999) 35-47
2. Ramos-Casals M., Jara L.J., Medina F., Rosas J., Calvo-Aven J., Mana J., et al., HISPAMEC Study Group. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J. Intern. Med. 257 (2005) 549-557
3. Cacoub P., Poynard T., Ghillani P., Charlotte F., Olivi M., Piette J.M., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Arthritis Rheum. 42 (1999) 2204-2212
4. Lovy M.R., Starkebaum G., and Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J. Rheumatol. 23 (1996) 979-983
5. Zuckerman E., Keren D., Rozenbaum M., Toubi E., Slobodin G., Tamir A., et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin. Exp. Rheumatol. 18 (2000) 579-584
6. Rosner I., Rozenbaum M., Toubi E., Kessel A., Naschitz J.E., and Zuckerman E. The case for hepatitis C arthritis. Semin. Arthritis Rheum. 33 (2004) 375-387
7. Rivera J., Garcia-Monforte A., Pineda A., and Millan Nunez-Cortes J. Arthritis in patients with chronic hepatitis C virus infection. J. Rheumatol. 26 (1999) 420-424
8. Taglione E., Vatteroni M.L., Martini P., Galluzzo E., Lombardini F., Delle Sedie A., et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J. Rheumatol. 26 (1999) 370-372
9. Maillefert J.F., Muller G., Falgarone G., Bour J.B., Ratovohery D., Dougados M., et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann. Rheum. Dis. 61 (2002) 635-637
10. Lienesch D., Morris R., Metzger A., Debuys P., and Sherman K. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J. Rheumatol. 32 (2005) 489-493
11. Bombardieri M., Alessandri C., Labbadia G., Iannuccelli C., Carducci F., Riccieri V., et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res. Ther. 6 (2004) 137-141
12. Wener M.H., Hutchinson K., Morishima C., and Gretch D.R. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 50 (2004) 2305-2308
13. Palazzi C., Olivieri I., Cacciatore P., Pennese E., and D'Amico E. Management of hepatitis C virus-related arthritis. Expert Opin. Pharmacother. 6 (2005) 27-34
14. Nissen M.J., Fontanges E., Allam Y., Zoulim F., Trepo C., and Miossec P. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatol. 44 (2005) 1016-1020
15. Parke F.A., and Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 51 (2004) 800-804
16. Ito H., Ito H., Nagano M., Nakano S., Shigeyoshi Y., and Kusaka H. In situ identification of hepatitis C virus RNA in muscle. Neurology 64 (2005) 1073-1075
17. Buskila D., Shnaider A., Neumann L., Zilberman D., Hilzenrat N., and Sikuler E. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch. Intern. Med. 157 (1997) 2497-2500
18. Kozanoglu E., Canataroglu A., Abayli B., Colakoglu S., and Goncu K. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol. Int. 23 (2003) 248-251
19. Narvaez J., Nolla J.M., and Valverde-Garcia J. Lack of association of fibromyalgia with hepatitis C virus infection. J. Rheumatol. 32 (2005) 1118-1121
20. Rivera J., de Diego A., Trinchet M., and Garcia Monforte A. Fibromyalgia-associated hepatitis C virus infection. Br. J. Rheumatol. 36 (1997) 981-985
21. Mariette X. Hepatitis C virus, arthritides, and arthromyalgia. Joint Bone Spine 70 (2003) 246-247
22. Ferri C., Giuggioli D., Cazzato M., Sebastiani M., Mascia M.T., and Zignego A.L. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin. Exp. Rheumatol. 21 Suppl. (2003) 78-84
23. Sansonno D., Cornacchiulo V., Iacobelli A.R., Di Stefano R., Lospalluti M., and Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 21 (1995) 305-312
24. Vallat L., Benhamou Y., Gutierrez M., Ghillani P., Hercher C., Thibault V., et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum. 50 (2004) 3668-3678
25. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
26. Cacoub P., Renou C., Kerr G., Hue S., Rosenthal E., Cohen P., et al. Influence of HLA DR11 phenotype on the risk of hepatitis C virus associated mixed cryoglobulinemia. Arthritis Rheum. 44 (2001) 2118-2124
27. Lenzi M., Frisoni M., Mantovani V., Ricci P., Muratori L., Francesconi R., et al. Haplotype HLA B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 91 (1998) 2062-2066
28. Persico M., De Marino F.A., Di Giacomo Russo G., Persico E., Morante A., Palmentieri B., et al. Prevalence and incidence of cryoglobulins in hepatitis C virus-related chronic hepatitis patients: a prospective study. Am. J. Gastroenterol. 98 (2003) 884-888
29. Sene D., Ghillani-Dalbin P., Thibault V., Guis L., Musset L., Duhaut P., et al. Long-term course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J. Rheumatol. 31 (2004) 2199-2206
30. Ferri C., Sebastiani M., Giuggioli D., Cazzato M., Longombardo G., Antonelli A., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin. Arthritis Rheum. 33 (2004) 355-374
31. Sene D., Limal N., and Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab. Brain Dis. 19 (2004) 357-381
32. Cacoub P., Saadoun D., Limal N., Sene D., Lidove O., and Piette J.C. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 52 (2005) 911-915
33. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P.L., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med. 330 (1994) 751-756
34. Dammacco F., Sansonno D., Han J.H., Shyamala V., Cornacchiulo V., Iacobelli A.R., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84 (1994) 3336-3343
35. Cacoub P., Lidove O., Maisonobe T., Duhaut P., Thibault V., Ghillani P., et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 46 (2002) 3317-3326
36. Zuckerman E., Keren D., Slobodin G., Rosner I., Rozenbaum M., Toubi E., et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J. Rheumatol. 27 (2000) 2172-2178
37. Mazzaro C., Zorat F., Caizzi M., Donada C., Di Gennaro G., Maso L.D., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J. Hepatol. 42 (2005) 632-638
38. Saadoun D., and Cacoub P. Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia. J. Hepatol. 43 (2005) 737
39. Vassilopoulos D., and Calabrese L.H. Rheumatic manifestations of hepatitis C infection. Curr. Rheumatol. Rep. 5 (2003) 200-204
40. Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann. Rheum. Dis. 62 (2003) 1230-1233
41. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacity and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
42. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., and Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD 20. Blood 101 (2003) 38118-38138
43. Chandesris M.O., Gayet S., Schleinitz N., Doudier B., Harle J.R., and Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatol. 43 (2004) 532-533
44. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatol. 41 (2002) 1126-1132
45. de Dios Garcia-Diaz J., Garcia-Sanchez M., Busteros J.I., and Arcos P. Polyarteritis nodosa after interferon treatment for chronic hepatitis C. J. Clin. Virol. 32 (2005) 181-182
46. Haddad J., Deny P., Munz-Gotheil C., Ambrosini J.C., Trinchet J.C., Pateron D., et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339 (1992) 321-323
47. Ramos-Casals M., Loustaud-Ratti V., De Vita S., Zeher M., Bosch J.A., Toussirot E., et al., SS-HCV Study Group. Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine 84 (2005) 81-89
48. Toussirot E., Le Huede G., Mougin C., Balblanc J.C., Bettinger D., and Wendling D. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjogren's syndrome and hepatitis C virus infection. J. Rheumatol. 29 (2002) 2382-2385
49. Koike K., Moriya K., Ishibashi K., Yotsuyanagi H., Shintani Y., Fujie H., et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc. Natl. Acad. Sci. USA 94 (1997) 233-236
50. Doffoel-Hantz V., Loustaud-Ratti V., Ramos-Casals M., Alain S., Bezanahary H., Liozon E., et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev. Med. Interne 26 (2005) 88-94
51. Loustaud-Ratti V., Riche A., Liozon E., Labrousse F., Soria P., Rogez S., et al. Prevalence and characteristics of Sjogren's syndrome or sicca syndrome in chronic hepatitis C virus infection: a prospective study. J. Rheumatol. 28 (2001) 2245-2251
52. Leclerc S., Myers R.P., Moussalli J., Herson S., Poynard T., and Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur. J. Intern. Med. 14 (2003) 237-243
53. Ramos-Casals M., Mana J., Nardi N., Brito-Zeron P., Xaubet A., Sanchez-Tapias J.M., et al., HISPAMEC Study Group. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine 84 (2005) 69-80
54. Ramos-Casals M., Font J., Garcia-Carrasco M., Cervera R., Jimenez S., Trejo O., et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum. 43 (2000) 2801-2806
55. Kowdley K.V., Subler D.E., Scheffel J., Moore B., and Smith H. Hepatitis C virus antibodies in systemic lupus erythematosus. J. Clin. Gastroenterol. 25 (1997) 437-439
56. Ramos-Casals M., and Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr. Opin. Rheumatol. 17 (2005) 447-455
57. Ramos-Casals M., Cervera R., Lagrutta M., Medina F., Garcia-Carrasco M., de la Red G., et al., Hispanoamerican Study Group of Autoimmune Manifestations of Chronic Viral Disease (HISPAMEC). Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin. Infect. Dis. 38 (2004) 1009-1016
58. Manganelli P., Giuliani N., Fietta P., Mancini C., Lazzaretti M., Pollini A., et al. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?. Clin. Rheumatol. 24 (2005) 296-300
59. Fiore C.E., Riccobene S., Mangiafico R., Santoro F., and Pennisi P. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. Osteoporos. Int. 16 (2005) 2180-2184